MarketPulse

PF-07307405

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pfizer-Valneva Lyme Vaccine Clears Phase 3 with 70%+ Efficacy in Pivotal Trial

Pfizer and Valneva's Lyme disease vaccine demonstrates 70%+ efficacy in Phase 3 trials, advancing toward potential regulatory approval after decades without preventive options.
PFEVALNPhase 3 trialLyme disease vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pfizer-Valneva Lyme Vaccine Shows 70%+ Efficacy, Advancing Key Development Milestone

Pfizer and Valneva's experimental Lyme disease vaccine demonstrated over 70% efficacy in Phase 3 trials for children and adults aged five and older.
PFEVALNPhase 3 trialLyme disease vaccine